Evidence map›Paper›PMID 40769716›Full record

ReviewBiomolecules & therapeutics2025

Chitinase-3-Like Protein 1 as a Therapeutic Target for Inflammatory Diseases.

Sun Mi Gu, Tae Hun Kim, Jeong Ho Park, Key-Hwan Lim, Po Myoung Jun, Yong Sun Lee, Gi Ryang Kweon, Jin Tae Hong

Abstract readReview
In one paragraph

Review in Biomolecules & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sun Mi GuCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju 28160, Republic of Korea.
Tae Hun KimCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju 28160, Republic of Korea.
Jeong Ho ParkWhata Bio Co. Ltd., Seoul 05836, Republic of Korea.
Key-Hwan LimCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju 28160, Republic of Korea.
Po Myoung JunCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju 28160, Republic of Korea.
Yong Sun LeeCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju 28160, Republic of Korea.
Gi Ryang KweonDepartment of Biochemistry, College of Medicine, Chungnam National University School of Medicine, Daejeon 35015, Republic of Korea.
Jin Tae HongCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju 28160, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chitinase-3-like protein 1 (CHI3L1) is a secreted glycoprotein involved in macrophage polarization, apoptosis, and inflammation, and carcinogenesis. The expression of CHI3L1 is significantly increased in various inflammatory and immunological diseases, such as rheumatoid arthritis, Alzheimer's disease, and atopic dermatitis. Several studies suggest that CHI3L1 may be a viable therapeutic target for these diseases, given its ability to release various pro-inflammatory cytokines, including interleukin (IL)-1β, IL-4, IL-6, IL-13, tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). Therefore, CHI3L1 likely plays a role in the development of a broad spectrum of inflammatory diseases. However, the precise pathophysiological and pharmacological mechanisms by which CHI3L1 contributes to these diseases remain to be fully elucidated. This review synthesizes recent findings on the functional roles of CHI3L1 across diverse inflammatory conditions, highlighting its involvement in critical signaling pathways. Moreover, preclinical research underscores the therapeutic potential of CHI3L1 inhibition. Thus, targeted CHI3L1 interventions represent a compelling therapeutic strategy warranting further clinical exploration and validation.

Indexed as

Chitinase-3-like protein 1Inflammatory diseasesTherapeutic target

Identifiers

PMID40769716
PMCPMC12408202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.